Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Helmers

Thoracic Surgery (Cardiothoracic Vascular Surgery) Atlanta, GA Medical Doctor

NPI 1518207018 CMS profile 3082192

95 Collier Rd Nw Ste 5015, Atlanta, GA 30309

Open in the dashboard

General payments

$31,945

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Helmers of Atlanta, GA is reported in the CMS Open Payments database as having received $31,945 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,828 61
2024 General $1,575 22
2023 General $1,528 19
2022 General $1,696 13
2021 General $5,248 23
2020 General $978 7
2019 General $3,093 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Helmers
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Mark Helmers were reported at $17,828. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Mark Helmers Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $3,093 $886 $178–$3,167 $163
2020 $978 $341 $108–$1,605 $114
2021 $5,248 $453 $125–$1,886 $132
2022 $1,696 $695 $180–$2,566 $149
2023 $1,528 $745 $205–$2,662 $160
2024 $1,575 $799 $214–$2,967 $164
2025 $17,828 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $19,073 59 payments
  2. Atricure, Inc. $3,586 34 payments
  3. Medtronic, Inc. $2,207 16 payments
  4. W. L. Gore & Associates, Inc. $1,809 10 payments
  5. Bolton Medical Inc $1,674 11 payments
  6. CryoLife, Inc. $900 10 payments
  7. Baxter Healthcare $724 9 payments
  8. Medtronic Vascular, Inc. $582 4 payments
  9. Abbott Laboratories $566 6 payments
  10. Medical Device Business Services, Inc. $399 6 payments
  11. Other $427 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $12,880 2 payments
  2. Food and Beverage $9,370 126 payments
  3. Travel and Lodging $8,916 40 payments
  4. Education $780 7 payments
Products named General payments · program years 2019–2025
  1. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $11,299 6 payments
  2. SYNERGY ABLATION SYSTEM $2,174 18 payments
  3. Valiant Captivia $1,904 12 payments
  4. GORE TAG Thoracic Endoprosthesis $1,809 10 payments
  5. SAPIEN 3 Ultra RESILIA $1,671 15 payments
  6. ATRICURE SYNERGY ABLATION SYSTEM $1,011 10 payments
  7. INSPIRIS RESILIA aortic valve $938 10 payments
  8. AtriCure cryoICE cryoSPHERE Cryoablation System $928 3 payments
  9. Grafts $922 2 payments
  10. Cardiac non-SynerGraft $798 8 payments
  11. Other $5,345 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Thoracic Surgery: 42

Drug cost

$132

Median for Thoracic Surgery: $318

Branded share of claims

100%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 18 $132

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$58,513

Medicare's payments for the services billed

Medicare patients

74

Average age 76

Services billed

131

37 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Diabetes 50%
Chronic kidney disease 49%
Arthritis 49%
Atrial fibrillation 36%
COPD 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record